Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 577-skin-graft-except-for-skin-ulcer-or-cellulitis-with-cc
    Ask Trek AI about this page

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    DRG 577 groups inpatient admissions for skin graft procedures excluding skin ulcer or cellulitis when a Complication or Comorbidity is present, covering grafting for trauma, burns, and surgical defects. Understanding this Diagnosis-Related Group is important because the presence of a Complication or Comorbidity influences resource intensity and Medicare inpatient reimbursement under Centers for Medicare & Medicaid Services payment policies.

    Customize your policy alerts

    Sign up for drg 577 policy alerts

    Get alerted when payer policies referencing 577 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 577 Overview

    DRG 577 covers inpatient admissions for skin graft procedures excluding cases primarily for skin ulcer or cellulitis when a Complication or Comorbidity is present. Typical cases include split-thickness or full-thickness grafting for traumatic wounds, burns, or surgical defects where additional clinical complexity influences resource use. This Diagnosis-Related Group matters for Medicare payment because it groups similar clinical services and drives reimbursement based on the presence of Complication or Comorbidity, affecting payment relative to less or more complex graft admissions. Hospitals use this grouping to classify cases for inpatient prospective payment and billing under Centers for Medicare & Medicaid Services rules.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute perioperative wound-healing intervention trials assessing novel biologic dressings, growth-factor-containing scaffolds, or negative-pressure therapy protocols to improve graft take and reduce early complications. These studies enroll hospitalized adults undergoing split- or full-thickness skin grafting for traumatic wounds, burns, or surgical defects (excluding ulcers/cellulitis) and measure graft survival, reoperation for graft failure, infection rates, and length of stay. Results are directly relevant to surgeons and hospital payers because improved graft take and fewer complications shorten inpatient stays, reduce returns to the OR, and lower short-term resource utilization.
    • Comparative effectiveness studies of graft donor-site management and anesthesia/analgesia strategies that evaluate outcomes such as pain control, donor-site healing, and functional recovery. These trials commonly randomize patients receiving skin grafts to different donor-site dressings, local/regional block techniques, or opioid-sparing multimodal analgesia regimens, focusing on adult inpatients and early post-discharge recovery. Findings inform care pathways and bundled-payment decisions by identifying approaches that reduce nursing time, readmissions, and post-acute service use while maintaining graft success.
    • Post-discharge observational cohorts and registry-based outcomes research tracking long-term functional outcomes, scar quality, and healthcare utilization after skin grafting for non-ulcer/non-cellulitis indications. These studies follow patients after hospital discharge to quantify rates of reoperation, outpatient wound care needs, rehabilitation utilization, and patient-reported outcomes across various comorbidity profiles. This evidence helps payers and health systems predict downstream costs, design targeted care transitions, and stratify patients for intensive follow-up to prevent costly complications and readmissions.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.